登录

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces the same desired effect at a lower dose. It is noteworthy that both drugs exhibit similar maximum effect or Emax values, implying that they possess equal efficacy. Efficacy depends on the number of drug–receptor complexes formed and the extent of receptor activation. Maximal efficacy is achieved when all receptors are occupied, rendering further increases in drug concentration incapable of eliciting additional responses. Full agonists have high efficacy, as they activate receptors entirely and elicit a complete response. The efficacy of partial agonists is lower, as they activate receptors to a lesser extent. Antagonists, in contrast, exhibit zero efficacy by not activating the receptors. Instead, they act as blockers and either reduce the number of available receptors for agonist binding or induce conformational changes that prevent effective agonist binding. Overall, these factors play a crucial role in determining the efficacy and potency of drugs, which, in turn, can determine their usefulness in treating various medical conditions.

Tags
Dose response RelationshipPotencyEfficacyEC50 ValuesCandesartanIrbesartanMaximum EffectEmax ValuesDrug receptor ComplexesReceptor ActivationFull AgonistsPartial AgonistsAntagonistsDrug ConcentrationMedical Treatment

来自章节 4:

article

Now Playing

4.9 : Dose-Response Relationship: Potency and Efficacy

Pharmacodynamics

4.0K Views

article

4.1 : 药物作用原则

Pharmacodynamics

5.5K Views

article

4.2 : 药物作用的目标:概述

Pharmacodynamics

5.2K Views

article

4.3 : 信号转导:概述

Pharmacodynamics

8.0K Views

article

4.4 : 换能器机制:G 蛋白偶联受体

Pharmacodynamics

1.7K Views

article

4.5 : 配体门控离子通道受体:门控机制

Pharmacodynamics

2.0K Views

article

4.6 : 换能器机制:酶联受体

Pharmacodynamics

2.2K Views

article

4.7 : 换能器机制:核受体

Pharmacodynamics

1.2K Views

article

4.8 : 剂量-反应关系:概述

Pharmacodynamics

2.7K Views

article

4.10 : 剂量-反应关系:选择性和特异性

Pharmacodynamics

6.1K Views

article

4.11 : 治疗指数

Pharmacodynamics

3.9K Views

article

4.12 : 药物-受体相互作用:激动剂

Pharmacodynamics

2.2K Views

article

4.13 : 药物-受体相互作用:拮抗剂

Pharmacodynamics

2.4K Views

article

4.14 : 药物的综合作用:拮抗作用

Pharmacodynamics

7.5K Views

article

4.15 : 药物的综合作用:协同作用

Pharmacodynamics

3.1K Views

See More

JoVE Logo

政策

使用条款

隐私

科研

教育

关于 JoVE

版权所属 © 2025 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。